The team compared semaglutide — in the form of Ozempic — with seven otherdiabetesmedications like metformin, insulin, and liraglutide, which belongs to the same drug class as semaglutide.
the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients compared with seven otherdiabetesmedications.